期刊
MMWR RECOMMENDATIONS AND REPORTS
卷 65, 期 3, 页码 1-103出版社
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.15585/mmwr.rr6503a1
关键词
-
资金
- Bayer
- Medicines360
- Contramed
- Merck
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Society of Family Planning
- National Institutes of Health
- Gates Foundation
- World Health Organization
- Contemporary Forum
- American Congress of Obstetricians and Gynecologists
- U.S. Food and Drug Administration, Reproductive and Drug Advisory Committee for U.S. Food and Drug Administration
- Wayne State University
- Telluride Conference
- New Mexico Department of Health Clinician Conference
- Planned Parenthood National Medical Conference
- British Columbia Contraception Access Research Team Conference
- American Congress of Obstetricians and Gynecologists annual meeting
- Bayer Women's Health
- Prima-Temp
- Teva Pharmaceutical Industries, Ltd.
- Family Planning and Society of Family Planning Research Fund
- Agile Therapeutics
- Alnylam Pharmaceuticals
- Gilead Sciences
- National Heart, Lung, and Blood Institute
- Pfizer
- Society for Women's Health Research
- Leon Farma
The 2016 U.S. Medical Eligibility Criteria for Contraceptive Use (US. MEC) comprises recommendations for the use of specific contraceptive methods by women and men who have certain characteristics or medical conditions. These recommendations for health care providers were updated by CDC after review of the scientific evidence and consultation with national experts who met in Atlanta, Georgia, duringAugust 26-28, 2015. The information in this report updates the 2010 U.S. MEC (CDC. U.S. medical eligibility criteria for contraceptive use, 2010. MMWR 2010:59 [No. RR-4]). Notable updates include the addition of recommendations for women with cystic fibrosis, women with multiple sclerosis, and women receiving certain psychotropic drugs or St. John's wort; revisions to the recommendations for emergency contraception, including the addition of ulipristal acetate; and revisions to the recommendations for postpartum women; women who are breaseeding; women with known dyslipidemias, migraine headaches, superficial venous disease, gestational trophoblastic disease, sexually transmitted diseases, and human immunodeficiency virus; and women who are receiving antiretroviral therapy. The recommendations in this report are intended to assist health care providers when they counsel women, men, and couples about contraceptive method choice. Although these recommendations are meant to serve as a source of clinical guidance, health care providers should always consider the individual clinical circumstances of each person seeking family planning services. This report is not intended to be a substitute for professional medical advice for individual patients. Persons should seek advice from their health care providers when considering family planning options.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据